Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Summary
The Targeted Agent and Profiling Utilization Registry (TAPUR) is an ongoing American Society of Clinical Oncology (ASCO)-sponsored pragmatic clinical trial that matches patients with advanced cancers to FDA-approved targeted therapies based on their tumor's genomic profile, even when those drugs are not approved for their specific cancer type. This registry study aims to generate real-world evidence on the effectiveness of genomically-matched targeted therapies across multiple tumor types and biomarker combinations, with results published for individual cohorts as they become available. The study represents a large-scale precision oncology initiative designed to expand access to targeted agents while systematically collecting outcomes data.
Plain Language Summary
This study connects cancer patients whose tumors have specific genetic changes with drugs that target those changes, even if the drug wasn't originally approved for their type of cancer. Scientists are tracking how well these matched treatments work across many different cancers. The goal is to learn whether matching drugs to tumor genetics helps patients, regardless of where their cancer started.
Key Implications
- Patients with advanced cancers who have actionable genomic alterations but have exhausted standard treatment options may gain access to targeted therapies through this trial, though individual responses will vary
- Results from completed cohorts may inform future drug approvals for new cancer types based on shared genetic features rather than tumor location, a shift toward tissue-agnostic oncology
- The registry approach generates real-world evidence that complements traditional clinical trials, though this pragmatic design has inherent limitations compared to randomized controlled trials
Patient Relevance
Who This Affects
patients with advanced solid tumors or blood cancers who have a known targetable genomic alteration, have exhausted standard treatment options, and have access to a participating TAPUR study site